Navigation Links
Cause of effectiveness discovered for a cirrhosis treatment useful in 40 percent of patients
Date:2/27/2008

This release is available in Spanish.

Scientists of the Center for Applied Medical Research (CIMA) of the University of Navarra have discovered the molecular mechanism responsible for the effectiveness of an existing treatment for primary biliary cirrhosis, which combines two substances in order to produce an effect that does not result from either substance separately. The discovery involved the role played by the AE2 protein when the patient is treated with a combination of ursodeoxycholic acid (UDCA) together with glucocorticoids. The research results were recently published in The Journal of Clinical Investigation.

The origin of primary biliary cirrhosis (PBC)-which mostly affects middle-aged women-is still not understood. This pathology is associated with autoimmune phenomena, damage to the biliary vessels of the liver, and a reduction in the production of bile.

In Spain more than 1,000 cases are diagnosed each year, and the total number of patients worldwide is greater than 15,000. Dr. Juan Francisco Medina, Director of the Laboratory of Molecular Genetics of the CIMA, explains that in the present day the diagnosis of this disease, which is generally detected early, permits treatment with UDCA, which is effective in over half of the patients. However, nearly 40% of PBC patients do not respond satisfactorily to monotherapy with UDCA. Therefore, we looked for a combined treatment, and discovered that the combination of UDCA with glucocorticoids was a promising treatment for this group of patients. Those who suffer from this type of cirrhosis have a deficit of AE2, which is the protein for the secretion of bicarbonate in the bile.

The possibility of more cures with fewer transplants

The originality of this recently-published research article consists in relating, for the first time, the combined treatment with UDCA and glucocorticoids with a greater quantity of bicarbonate in the bile, and an improvement of the production of bile by the liver. Specifically, experiments in animal models and cell cultures demonstrate that only the combined treatment with UDCA and glucocorticoids increases the genetic expression of the human protein AE2 in the liver.

Based on available data, Dr. Medina considers that it is advisable to use combined treatment in those cases which present a poor response to monotherapy with UDCA. He proposes the use of a corticoid such as budesonida, which has fewer side effects than cortisone and prednisone. If, for fear of side effects, we allow the disease to progress, it is very probable that the only treatment will be a transplant. On the other hand, if this treatment option is confirmed as successful, it could reduce the number of transplants required in order to save the lives of patients.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Study Points to Cause of Vioxx Heart Risk
3. Damp, Moldy Homes May Cause Depression
4. Constipations Many Causes and Cures
5. High Co-Pays Cause Seniors to Go Without Meds
6. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
7. Vocal cord dysfunction may be caused by work
8. Study finds drug spending caps cause some seniors to quit taking key medicines
9. Medicare Spending Caps Cause Seniors to Stop Meds
10. Gene Mutations May Cause Rare Neonatal Diabetes
11. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... The threat of ... to work for a company involved in the underground testing of nuclear weapons. Years ... for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical ...
(Date:2/27/2017)... ... 2017 , ... Orange County dentist, Dr. A. Rassouli, comments on ... when the bacteria in plaque infect the gums and other tissues supporting the teeth. ... planing or SRP, and can include surgical therapies if the condition has led to ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
Breaking Medicine Technology: